Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
January 2020
-
Key ReleaseSandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicinesSuccessful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements…
-
Media ReleaseNovartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitisNew Cosentyx® (secukinumab) US label to include 300 mg up-titration option is based on Phase III MEASURE 3 study results in ankylosing spondylitis (AS)1 Label update provides clinicians with…
-
Featured NewsNovartis 2019 Financial Results
Novartis announces the company’s fourth quarter and 2019 full year financial results.
-
Key ReleaseNovartis a réalisé en 2019 une forte croissance de son chiffre d’affaires, une augmentation de sa marge et une percée dans l’innovation en lançant cinq nouvelles entités moléculairesHausse du chiffre d’affaires net des activités poursuivies1 de 9% sur l’exercice entier (tcc2, +6% USD): Pharmaceuticals: cette unité opérationnelle progresse de 12% (tcc), sous l’impulsion de…
-
Key ReleaseNovartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and…
-
Key ReleaseNovartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer WirkstoffeDer Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von Cosentyx (USD 3,6 …
-
Featured NewsNovartis at the World Economic Forum Annual Meeting Davos 2020
From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.
-
Media ReleaseNovartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active diseaseMayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent…
-
Featured NewsNovartis at J.P Morgan 2020
From January 13-16 2020, Novartis attended the J.P Morgan Healthcare Conference in San Francisco.
-
Sourcing innovation, strategically
Phil Gotwals talks about his vision for the future of business development for research.
-
Media ReleaseNovartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticariaData show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly higher affinity than current standard of care Xolair (omalizumab)1 …
Pagination
- ‹ Previous page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- …
- 152
- › Next page